Every Form 4 that C4 Therapeutics, Inc. (CCCC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CCCC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCCC filings page.
C4 Therapeutics, Inc. director Kenneth Carl Anderson acquired 3,662 common shares on October 1, 2026, issued under the company’s Non-Employee Director Compensation Policy after he elected shares in lieu of cash compensation for director services. The reported $3.14 per-share figure is based on the issuer’s closing market price that day. His direct common-stock holdings were 75,612 shares following the transaction.
Five additional common-stock positions were reported through trusts. Anderson disclaimed beneficial ownership of those shares except to the extent of his pecuniary interest.
C4 Therapeutics, Inc. director Donna Roy Grogan acquired 4,618 shares of common stock on October 1, 2026, under the company’s Non-Employee Director Compensation Policy. She elected to receive shares in lieu of cash compensation for her director services. The reported price was $3.14 per share, based on the closing market price that day; her direct holdings following the transaction were 79,471 shares.
C4 Therapeutics, Inc. (CCCC) reported that Chief Financial Officer Kendra Adams had restricted stock units vest on September 18, 2026, resulting in the acquisition of 6,250 shares of Common Stock. Of these, 2,775 shares were withheld by the company to satisfy tax withholding obligations related to the RSU vesting and settlement, which is not characterized as a market sale.
C4 Therapeutics, Inc. reported equity compensation activity for Chief Medical Officer Leonard Reyno. On July 10, 2026, Reyno acquired 15,325 shares of common stock upon vesting of previously granted restricted stock units. In a related move, 7,397 shares were withheld by the company to cover tax obligations associated with this vesting, which the company states does not represent an open-market sale.
Anderson Kenneth Carl reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics, Inc. director Kenneth C. Anderson received an equity award of common stock rather than cash fees for his board service. On July 1, 2026, he was granted 2,650 shares at a value based on the closing market price of $4.34 per share, in line with the company’s Non-Employee Director Compensation Policy. Following this compensation grant, Anderson directly holds 71,950 common shares. Additional shares are held indirectly through several Anderson family revocable and irrevocable trusts, for which he disclaims beneficial ownership except for any pecuniary interest.
GROGAN DONNA ROY reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics director Donna Roy Grogan received a grant of 3,341 shares of common stock on July 1, 2026. The shares were issued under the company’s Non-Employee Director Compensation Policy, as she elected stock instead of cash fees, bringing her direct holdings to 74,853 shares.
C4 Therapeutics, Inc. director Owen Hughes received a grant of stock options covering 62,000 shares of common stock. The options have an exercise price of $4.2500 per share and expire on June 23, 2036. Following this grant, Hughes holds options on 62,000 shares directly.
According to the vesting terms, the option becomes fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, provided Hughes continues serving on the Board through that date.
C4 Therapeutics, Inc. director Steven L. Hoerter received a grant of stock options covering 62,000 shares of Common Stock. The options have an exercise price of $4.25 per share and expire on June 23, 2036.
According to the footnote, the entire option vests and becomes exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, assuming he continues to serve on the Board through that date. After this grant, he holds 62,000 options directly.
C4 Therapeutics, Inc. director Utpal Koppikar received a grant of stock options to buy 62,000 shares of common stock. The options have an exercise price of $4.25 per share and expire on June 23, 2036.
The option award will vest and become exercisable in full on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as he continues serving on the Board through that date. Following this grant, he holds options covering 62,000 shares directly.
C4 Therapeutics director Kenneth Carl Anderson received a grant of stock options as part of his compensation. The award covers 62,000 options to buy Common Stock at an exercise price of $4.25 per share, with no cash paid at grant.
The options vest and become exercisable in full on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, provided he continues serving on the Board through that date. The options expire on June 23, 2036 if not exercised.
C4 Therapeutics director Ronald Harold Wilfred Cooper received a grant of stock options covering 62,000 shares of common stock. The options have an exercise price of $4.25 per share and were awarded at no cost to him.
These options vest and become fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as he continues serving on the board through that date. After this grant, his reported holdings of this option award total 62,000 derivative securities.
C4 Therapeutics director Laura Bessen received a new stock option grant covering 62,000 shares of common stock. The option has an exercise price of $4.25 per share and expires on June 23, 2036. This is a compensation-related award, not an open‑market trade.
According to the terms, the option vests and becomes fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as Bessen continues serving on the board through that date. After this grant, she holds 62,000 derivative securities directly.
C4 Therapeutics director Stephen Fawell was granted stock options linked to 62,000 shares of common stock. The options carry an exercise price of $4.25 per share and expire on June 23, 2036. This is a compensation-related award, not an open-market purchase.
The option grant vests and becomes exercisable in full on the earlier of June 24, 2027 or the next annual meeting of stockholders, as long as he continues serving on the Board. Following this grant, he holds options covering 62,000 shares directly.
C4 Therapeutics director Donna Roy Grogan received a new stock option grant. She was awarded options covering 62,000 shares of Common Stock at an exercise price of $4.25 per share. These options are a compensation-related award, not an open-market stock purchase or sale.
The option will vest and become fully exercisable on the earlier of June 24, 2027 or the company’s next annual meeting of stockholders, provided she continues serving on the Board through that date. Following this grant, her reported holdings in this option award total 62,000 derivative securities.
C4 Therapeutics director Kenneth Carl Anderson exercised stock options to acquire 1,070 shares of common stock on June 1, 2026. The options were exercised at a price of $2.11 per share for cash, and no shares were sold in connection with the exercise.
Following the exercise, Anderson directly holds 69,300 shares of C4 Therapeutics common stock. Additional shares are held indirectly through several revocable and irrevocable trusts associated with Anderson and Cynthia E. Anderson, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Anderson Kenneth Carl reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics director Kenneth Carl Anderson received a grant of 4,259 shares of common stock of C4 Therapeutics, Inc. as compensation for his services as a non-employee director, in lieu of cash fees. The grant was valued at $2.70 per share, based on the closing market price on April 1, 2026. Following this award, he holds 68,230 shares directly, and additional shares are held indirectly through several irrevocable and revocable trusts, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
GROGAN DONNA ROY reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics director Donna Roy Grogan received 5,370 shares of common stock as compensation. The shares were issued under the company’s Non-Employee Director Compensation Policy, where she elected stock instead of cash fees for board service.
The value was based on the closing market price of $2.70 per share on April 1, 2026. After this grant, she directly holds 71,512 shares of C4 Therapeutics common stock.
C4 Therapeutics Chief Business Officer Scott N. Boyle reported equity compensation activity in C4 Therapeutics, Inc. common stock. On February 13, 2026, he received a grant of 200,000 restricted stock units (RSUs), with 100,000 RSUs vesting in three equal annual installments starting February 13, 2027, and 100,000 RSUs vesting in full on February 13, 2029, subject to performance milestones. On February 13 and 14, 2026, previously granted RSUs vested, resulting in the acquisition of 25,950 shares of common stock through derivative exercises, while 9,004 shares were withheld by the company at $1.89 per share to satisfy tax obligations, which the filing states does not represent an open market sale. After these transactions, Boyle directly owned 298,801 shares of common stock.
C4 Therapeutics, Inc. reported equity compensation and related share movements for Chief Scientific Officer Paige Mahaney. On February 13, 2026, Mahaney received a grant of 240,000 restricted stock units (RSUs). Of these, 120,000 RSUs will vest in three equal annual installments starting on February 13, 2027, and 120,000 RSUs will vest in full on February 13, 2029, with the latter portion subject to performance milestones.
On February 14, 2026, Mahaney acquired 7,050 shares of common stock upon vesting of a previously disclosed RSU grant, and 2,446 shares were withheld by the company to cover tax obligations, which the filing states does not represent a sale. After these transactions, Mahaney directly owned 336,910 shares of common stock.
C4 Therapeutics Chief People Officer Kelly Schick reported several equity compensation transactions in Common Stock. Schick received a grant of 200,000 restricted stock units, with 100,000 vesting in three equal annual installments starting on February 13, 2027 and 100,000 vesting in full on February 13, 2029, subject to performance milestones. Additional shares were acquired through the vesting of previously granted RSUs and by exercising derivative securities, while 7,269 and 1,735 shares were withheld to cover tax obligations, which the company notes do not represent market sales. Following these transactions, Schick directly owned 299,881 shares of Common Stock.
C4 Therapeutics, Inc. reported multiple equity transactions by President & CEO Andrew Hirsch. On February 13, 2026, he received 700,000 restricted stock units (RSUs). According to the disclosure, 350,000 RSUs vest in three equal annual installments beginning on February 13, 2027, and 350,000 RSUs vest in full on February 13, 2029, subject to potential acceleration if certain performance milestones are achieved.
On February 14 and 15, 2026, previously granted RSUs vested, resulting in acquisitions of common stock through derivative exercises and conversions. In connection with these vestings, the company withheld 39,154 and 9,057 shares of common stock at $1.89 per share to cover tax withholding obligations. The filing states these withheld shares do not represent sales by Hirsch. After these transactions, he continued to hold over one million shares directly.
C4 Therapeutics Chief Medical Officer Leonard Reyno reported multiple equity compensation transactions in company stock. On February 13, 2026, he received a grant of 240,000 restricted stock units (RSUs), with 120,000 RSUs vesting in three equal annual installments starting on February 13, 2027, and 120,000 RSUs vesting in full on February 13, 2029, subject to potential performance-based acceleration.
On February 14, 2026, previously disclosed RSU awards vested, resulting in the acquisition of 30,950 shares of common stock at no cost. On the same date, 16,579 shares were withheld by the company at $1.89 per share to cover tax obligations related to the RSU vesting, which the filing states does not represent a sale. Following these transactions, Reyno directly owned 379,803 shares of common stock.
C4 Therapeutics, Inc. reported insider equity activity by Chief Financial Officer Kendra Adams. She received a grant of 240,000 restricted stock units (RSUs), which vest in stages through February 13, 2029, based on time and performance conditions.
Adams also acquired 30,950 and 3,750 shares of common stock through vesting and exercise of previously granted RSUs, and 15,381 and 1,863 shares were withheld by the company at $1.89 per share to cover tax obligations. After these transactions, she directly holds 385,098 shares of common stock.
C4 Therapeutics Chief Accounting Officer Mark Mossler reported equity compensation and related share movements. He received a grant of 56,980 restricted stock units, each representing one future share of common stock upon vesting and settlement.
According to the grant terms, 28,490 RSUs vest in three equal annual installments starting on February 13, 2027, and 28,490 RSUs vest in full on February 13, 2029, subject to performance milestones. Separately, 9,420 shares of common stock were acquired upon vesting of previously disclosed RSU awards, while 3,268 shares were withheld by the company at a price of $1.89 per share to cover tax obligations, which the filing specifies is not a sale. After these transactions, Mossler directly holds 71,916 shares of common stock.
C4 Therapeutics Chief Medical Officer Leonard Reyno reported an open-market sale of company stock. On January 16, 2026, he sold 10,000 shares of C4 Therapeutics, Inc. common stock at a price of $2.22 per share, as shown by transaction code "S" for a disposition. After this trade, he directly beneficially owns 156,382 shares of the company’s common stock.